Financial News

Eli Lilly is dominating one of the biggest growth markets in healthcare: the weight loss drug market.

For some experts, the outbreak is raising broader concerns about how equipped the U.S. is to respond to future infectious disease threats.

Democrat Sen. Peter Welch backs Trump's MFN drug pricing plan as bipartisan pressure over prescription costs grows.

A walkout at rival Samsung could hit about 3% of global memory-chip production, according to estimates.

A walkout at rival Samsung could hit about 3% of global memory-chip production, according to estimates.

Is LLY a good stock to buy? We came across a bullish thesis on Eli Lilly and Company on Value & Momentum Portfolio’s Substack. In this article, we will summarize the bulls’ thesis on LLY. Eli Lilly and Company’s share was trading at $987.05 as of May 6th. LLY’s trailing and forward P/E were 35.13 and 28.82 […]

On Tuesday, William Blair initiated coverage on Kailera Therapeutics Inc. (NASDAQ:KLRA), the latest entrant in the fast-growing weight-loss drug market. The obesity-focused biotech raised more than $600 million in April through an initial public offering of 39.06 million shares priced at $16 each. Kailera Portfolio ‘Strongly Mirrors’ Eli Lilly William Blair analyst Andy Hsieh said Kailera’s obesity pipeline could position the company as a future challenger in the expanding weight-loss market, ci

Japan's Takeda Pharmaceuticalplans to cut about 4,500 jobs in fiscal year2026, as it pushes ahead with a restructuring to centralizecorporate functions and reduce costs. The company...

LLY expands beyond tirzepatide with oral obesity pills and next-gen drugs like retatrutide to defend its lead in the booming weight-loss market.

Eli Lilly and Co. (NYSE:LLY) on Wednesday released detailed findings from two late-stage obesity studies showing patients were able to maintain significant weight loss after switching from higher-dose injectable incretin therapies to either Foundayo or lower-dose Zepbound. • Eli Lilly stock is showing upward bias. What should traders watch with LLY? The company presented data from the SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN studies at the 33rd European Congress on Obesity. The findings were also p

Micron Technology is on pace to close above the $900 billion market value for the first time, according to Dow Jones Market Data. The semiconductor company, whose stock is up 4.8% today, is on pace to become the 11th largest U.S. company by market cap.

Cathie Wood and Ross Gerber are both well known investors. Here's a look at the stocks they both hold across their ETFs.

ETFs like XLV stand out as aging U.S. demographics fuel rising demand for healthcare, medical devices and senior-focused care.

FEATURE Micron Technology stock was gaining early Wednesday. Labor unrest at Samsung Electronics could intensify the memory-chip supply crunch.  Micron shares were up 3.1% in early trading. Talks between Samsung and its labor union to avert a walkout collapsed on Wednesday.

If it feels like growth stocks can’t continue their outperformance much longer, ignore that feeling. The Vanguard S&P 500 Growth Index Fund Exchange-Traded Fund, home to companies with high sales growth including Nvidia Advanced Micro Devices Microsoft and Eli Lilly is up 13% in the past month. A couple of factors have driven the performance of the growth stocks.

Eli Lilly, Novo, JP Morgan, Coca-Cola, PepsiCO and Mondelez have been highlighted in this Investment Ideas article.

While the company has more publicly highlighted its AI developments in Europe, onboarding Vipin Gopal indicates its US division is ready to do more with this tech.

Eli Lilly (NYSE:LLY) reported new late phase clinical data on its obesity portfolio. Patients with obesity maintained significant long term weight loss after switching from injectable to oral therapies. The trials highlighted Foundayo and Zepbound as durable options for ongoing weight management and showed a consistent safety profile for the new oral GLP 1 therapy. Eli Lilly enters this update with its stock at $989.87 and 5 year share price gains of 432.2%. The company has also delivered a...

Novo Nordisk (NVO) faces semaglutide patent cliffs and looming generics—could profits drop 40%? Get valuation and HOLD insights now—read before you buy.

U.S.-based drugmaker Eli Lilly on Wednesday launched its Alzheimer's drug Lormalzi, also known as Donanemab, in India. Here are the details: o The drugmaker has priced the...

Eli Lilly and Co: Eli Lilly India: launches Lormalzi for Alzheimer's disease in India...

Eli Lilly and Company (NYSE: LLY) today announced detailed results from two late-phase trials showing that people with obesity maintained their weight loss long term with either Foundayo or lower-dose Zepbound after switching from higher doses of injectable incretin therapy. The findings from SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN, were presented at the 33rd European Congress on Obesity (ECO) and published in The Lancet and Nature Medicine, respectively.

'Mad Money' host Jim Cramer talks teh day's market action from the floor of the FedEx World Hub in Memphis.

Eli Lilly and Company (NYSE:LLY) today announced detailed results from two late-phase trials showing that people with obesity maintained their weight loss long term with either Foundayo or lower-dose Zepbound after

Mizuho's Jared Holz joins 'Fast Money' to talk the impact of FDA Commissioner Makary stepping down on healthcare stocks.

Analysts initiated covered Tuesday of IPO stock Kailera Therapeutics, a potential competitor to Lilly and Novo in obesity treatment.

Eli Lilly and Company (NYSE: LLY) today announced an initiative to support nationwide nutritious food distribution as part of the company's 150th anniversary, through charitable support of trusted community organizations in the United States. With Lilly's support, community organizations will be able to distribute approximately 500,000 meals to those in need across 15 communities. Lilly's support will also help one of these organizations build long-term cold storage infrastructure at 150 food pa

JNJ bets on Tremfya and newly approved Icotyde to drive immunology growth as Stelara faces biosimilar pressure.

With its best-in-breed GLP-1 drugs, Eli Lilly is beginning to cement itself as the dominant player in the massive GLP-1 market.